Comparative analysis of European guideline-based clinicopathological risk groups and the International Federation of Gynecology and Obstetrics staging system for endometrial cancer

IF 1.9 4区 医学 Q2 OBSTETRICS & GYNECOLOGY European journal of obstetrics, gynecology, and reproductive biology Pub Date : 2025-04-17 Epub Date: 2025-02-24 DOI:10.1016/j.ejogrb.2025.02.049
Mikko J. Loukovaara , Annukka M. Pasanen , Heini J. Lassus , Anna L. Luomaranta , Piret Hellberg , Johanna Vartiainen , Johanna E. Tapper , Ralf C. Bützow
{"title":"Comparative analysis of European guideline-based clinicopathological risk groups and the International Federation of Gynecology and Obstetrics staging system for endometrial cancer","authors":"Mikko J. Loukovaara ,&nbsp;Annukka M. Pasanen ,&nbsp;Heini J. Lassus ,&nbsp;Anna L. Luomaranta ,&nbsp;Piret Hellberg ,&nbsp;Johanna Vartiainen ,&nbsp;Johanna E. Tapper ,&nbsp;Ralf C. Bützow","doi":"10.1016/j.ejogrb.2025.02.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the correlation between endometrial cancer risk groups, as defined by the 2021 European guidelines, and the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system. Further, we aimed to evaluate the additional prognostic capability of the staging system within individual risk groups.</div></div><div><h3>Study design</h3><div>This retrospective cohort study included patients who underwent primary treatment for endometrial cancer at a single tertiary center. Each case was classified into a molecular-integrated risk group according to the 2021 joint guidelines from the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP). Staging was performed using the FIGO 2023 criteria with molecular classification.</div></div><div><h3>Results</h3><div>Data from 1044 patients were analyzed. Median follow-up was 70 months. Stage IA2, stage IB, and stage IVB were the most prevalent stages among the ESGO–ESTRO–ESP low-risk, intermediate risk, and advanced-metastatic groups, accounting for 80 %, 75 %, and 54 % of the cases, respectively. The stage distribution was more heterogeneous in the high-intermediate risk and high-risk groups, with stage IIA comprising 36 % and stage IICm<sub>p53abn</sub> comprising 35 % of cases in these groups. The FIGO staging system further stratified survival outcomes especially in the high-intermediate and high-risk groups. Stage IIC included a substantial number of cases from the intermediate risk (n = 23), high-intermediate risk (n = 48), and high-risk (n = 27) groups. Risk groups were associated with survival within this stage.</div></div><div><h3>Conclusions</h3><div>ESGO–ESTRO–ESP high-intermediate risk and high-risk endometrial cancers exhibited the greatest variability in terms of stage distribution and survival outcomes. Stage IIC, the most heterogeneous stage concerning risk groups, showed an association between risk groups and survival.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"308 ","pages":"Pages 85-89"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211525001186","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To investigate the correlation between endometrial cancer risk groups, as defined by the 2021 European guidelines, and the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system. Further, we aimed to evaluate the additional prognostic capability of the staging system within individual risk groups.

Study design

This retrospective cohort study included patients who underwent primary treatment for endometrial cancer at a single tertiary center. Each case was classified into a molecular-integrated risk group according to the 2021 joint guidelines from the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP). Staging was performed using the FIGO 2023 criteria with molecular classification.

Results

Data from 1044 patients were analyzed. Median follow-up was 70 months. Stage IA2, stage IB, and stage IVB were the most prevalent stages among the ESGO–ESTRO–ESP low-risk, intermediate risk, and advanced-metastatic groups, accounting for 80 %, 75 %, and 54 % of the cases, respectively. The stage distribution was more heterogeneous in the high-intermediate risk and high-risk groups, with stage IIA comprising 36 % and stage IICmp53abn comprising 35 % of cases in these groups. The FIGO staging system further stratified survival outcomes especially in the high-intermediate and high-risk groups. Stage IIC included a substantial number of cases from the intermediate risk (n = 23), high-intermediate risk (n = 48), and high-risk (n = 27) groups. Risk groups were associated with survival within this stage.

Conclusions

ESGO–ESTRO–ESP high-intermediate risk and high-risk endometrial cancers exhibited the greatest variability in terms of stage distribution and survival outcomes. Stage IIC, the most heterogeneous stage concerning risk groups, showed an association between risk groups and survival.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于欧洲指南的临床病理风险组与国际妇产科联合会子宫内膜癌分期系统的比较分析
目的探讨2021年欧洲指南定义的子宫内膜癌危险人群与2023年国际妇产科学联合会(FIGO)分期系统之间的相关性。此外,我们旨在评估分期系统在个体风险群体中的额外预后能力。研究设计:本回顾性队列研究纳入了在单一三级中心接受子宫内膜癌初级治疗的患者。根据欧洲妇科肿瘤学会(ESGO)、欧洲放射治疗与肿瘤学会(ESTRO)和欧洲病理学会(ESP) 2021年联合指南,将每个病例分类为分子整合风险组。采用FIGO 2023标准进行分期,并进行分子分类。结果共分析1044例患者资料。中位随访时间为70个月。IA2、IB和IVB阶段是ESGO-ESTRO-ESP低危、中危和晚期转移组中最常见的阶段,分别占80%、75%和54%的病例。在高、中危和高危人群中,分期分布更为异质性,IIA期占36%,IICmp53abn期占35%。FIGO分期系统进一步将生存结果分层,特别是在高、中、高危人群中。IIC期包括大量来自中危组(n = 23)、中高危组(n = 48)和高危组(n = 27)的病例。风险组与这一阶段的生存率相关。结论sesgo - estro - esp高、中危、高危子宫内膜癌在分期分布和生存结局方面差异最大。IIC期是风险组异质性最大的阶段,显示了风险组与生存率之间的关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.60
自引率
3.80%
发文量
898
审稿时长
8.3 weeks
期刊介绍: The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.
期刊最新文献
Home-telemonitoring of fetal and maternal condition in complicated pregnancies: Results from a real-world cohort to understand unplanned hospital visits and re-admissions The safety of vaginal delivery following obstetric anal sphincter injury- A retrospective pilot study using transperineal ultrasound algorithm Association between hypertensive disorders of pregnancy and long-term risk of cardiomyopathy: a systematic review, pairwise, and network meta-analysis Pretreatment decrease of the anti-müllerian hormone level does not translate into the proportionally lower efficiency of ovarian stimulation in patients with haematological malignancies A pre-post prospective study on the use of Transcutaneous Electrical Nerve Stimulation (TENS) unit in the management of endometriosis pain
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1